{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:41:12Z","timestamp":1790404872840,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.biopha.2006.07.086","type":"journal-article","created":{"date-parts":[[2006,8,29]],"date-time":"2006-08-29T08:23:44Z","timestamp":1156839824000},"page":"548-556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["Metastatic breast cancer: an\u00a0updating"],"prefix":"10.1016","volume":"60","author":[{"given":"A.","family":"Nicolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Giardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Carpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Anselmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Colosimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Giavaresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Miccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.biopha.2006.07.086_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.biopha.2003.09.003","article-title":"Advanced breast cancer: an update and controversies on diagnosis and therapy","volume":"57","author":"Nicolini","year":"2003","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.biopha.2006.07.086_bib2","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.1999.17.3.1080","article-title":"American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines","volume":"17","author":"Smith","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.biopha.2006.07.086_bib3","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1001\/jama.1994.03510440047031","article-title":"Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial","volume":"271","year":"1994","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.biopha.2006.07.086_bib4","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/jama.1994.03510440053032","article-title":"Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up","volume":"271","author":"Rosselli Del Turco","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2006.07.086_bib5","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.2741\/1926","article-title":"Biomolecular markers of breast cancer","volume":"11","author":"Nicolini","year":"2006","journal-title":"Front. Biosci."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2006.07.086_bib6","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/s00259-004-1523-z","article-title":"Circulating tumour markers in breast cancer","volume":"31","author":"Seregni","year":"2004","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"10.1016\/j.biopha.2006.07.086_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000076458","article-title":"Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations","volume":"24","author":"Nicolini","year":"2003","journal-title":"Tumour Biol."},{"issue":"9\u201310","key":"10.1016\/j.biopha.2006.07.086_bib8","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/sj.bjc.6690230","article-title":"The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy","volume":"79","author":"Nicolini","year":"1999","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.biopha.2006.07.086_bib9","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1054\/bjoc.2000.1477","article-title":"The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer","volume":"83","author":"Nicolini","year":"2000","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2006.07.086_bib10","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1200\/JCO.2002.20.3.620","article-title":"Can we cure limited metastatic breast cancer?","volume":"20","author":"Hortobagyi","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2006.07.086_bib11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1200\/JCO.2002.20.3.707","article-title":"Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer","volume":"20","author":"Nieto","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2006.07.086_bib12","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.1998.16.10.3439","article-title":"Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women","volume":"16","author":"Fossati","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2006.07.086_bib13","series-title":"The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort. Proc. ASCO Meeting Proceedings Chicago","author":"Chia","year":"2003"},{"issue":"3","key":"10.1016\/j.biopha.2006.07.086_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0002-9343(86)90286-X","article-title":"Metastatic breast cancer confined to the skeletal system. An indolent disease","volume":"81","author":"Sherry","year":"1986","journal-title":"Am. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2006.07.086_bib15","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/annonc\/mdg348","article-title":"Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients","volume":"14","author":"Koizumi","year":"2003","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2006.07.086_bib16","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1200\/JCO.1998.16.7.2401","article-title":"Construction and validation of a practical prognostic index for patients with metastatic breast cancer","volume":"16","author":"Yamamoto","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2006.07.086_bib17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/oxfordjournals.annonc.a058330","article-title":"Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group)","volume":"3","author":"Spataro","year":"1992","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2006.07.086_bib18","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/02841860410033721","article-title":"Proliferation rate, hormone receptor status and p53 expression in skeletal metastasis of breast carcinoma","volume":"43","author":"Wedin","year":"2004","journal-title":"Acta Oncol."},{"key":"10.1016\/j.biopha.2006.07.086_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/bjc.1996.2","article-title":"Oestrogen receptor: a stable phenotype in breast cancer","volume":"73","author":"Robertson","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2006.07.086_bib20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev.bi.41.070172.001223","article-title":"Mechanism of action of the female sex hormones","volume":"41","author":"Jensen","year":"1972","journal-title":"Annu. Rev. Biochem."},{"issue":"3","key":"10.1016\/j.biopha.2006.07.086_bib21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0277-5379(84)90084-1","article-title":"Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor","volume":"20","author":"Davis","year":"1984","journal-title":"Eur. J. Cancer Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2006.07.086_bib22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/oxfordjournals.annonc.a057790","article-title":"The process of malignant progression in human breast cancer","volume":"1","author":"Clarke","year":"1990","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2006.07.086_bib23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1075-122X.2004.21320.x","article-title":"The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women","volume":"10","author":"Buzdar","year":"2004","journal-title":"Breast J."},{"issue":"6","key":"10.1016\/j.biopha.2006.07.086_bib24","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1200\/JCO.2002.20.6.1467","article-title":"Elevated serum Her-2\/neu level predicts decreased response to hormone therapy in metastatic breast cancer","volume":"20","author":"Lipton","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2006.07.086_bib25","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.2001.19.10.2722","article-title":"Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer","volume":"19","author":"Burstein","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2006.07.086_bib26","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.biopha.2003.09.006","article-title":"Estrogen\/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies","volume":"57","author":"Lichtner","year":"2003","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.biopha.2006.07.086_bib27","first-page":"1643","article-title":"Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer","volume":"3","author":"Newby","year":"1997","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2006.07.086_bib28","first-page":"2087","article-title":"Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer","volume":"49","author":"Wright","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2006.07.086_bib29","first-page":"143","article-title":"Epidermal growth factor receptors and oestrogen receptor expression in breast cancer: relationship to endocrine sensitivity","volume":"12","author":"McClelland","year":"1993","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.biopha.2006.07.086_bib30","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1083\/jcb.129.5.1363","article-title":"bcl-2 overexpression inhibits cell death and promotes the morphogenesis, but not tumorigenesis of human mammary epithelial cells","volume":"129","author":"Lu","year":"1995","journal-title":"J. Cell Biol."},{"issue":"5","key":"10.1016\/j.biopha.2006.07.086_bib31","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.1997.15.5.1916","article-title":"bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study","volume":"15","author":"Elledge","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 4","key":"10.1016\/j.biopha.2006.07.086_bib32","doi-asserted-by":"crossref","first-page":"iv14","DOI":"10.1093\/annonc\/mdi902","article-title":"Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer","volume":"16","author":"Paradiso","year":"2005","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2006.07.086_bib33","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1046\/j.1445-2197.2003.02817.x","article-title":"Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer","volume":"73","author":"Holdaway","year":"2003","journal-title":"ANZ J. Surg."},{"issue":"10","key":"10.1016\/j.biopha.2006.07.086_bib34","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/cncr.11764","article-title":"Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma","volume":"98","author":"Manders","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2006.07.086_bib35","first-page":"1253","article-title":"Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer","volume":"9","author":"Berns","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.biopha.2006.07.086_bib36","first-page":"5407","article-title":"High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer","volume":"61","author":"Foekens","year":"2001","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2006.07.086_bib37","first-page":"1","article-title":"High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer","volume":"20","author":"Farquhar","year":"2005","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"10.1016\/j.biopha.2006.07.086_bib38","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1200\/JCO.2005.06.072","article-title":"Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial","volume":"23","author":"Schmid","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2006.07.086_bib39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bbmt.2005.10.009","volume":"12","author":"Vredenburgh","year":"2006","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"3","key":"10.1016\/j.biopha.2006.07.086_bib40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/01.coc.0000156917.43490.65","article-title":"High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants","volume":"28","author":"Dillman","year":"2005","journal-title":"Am. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2006.07.086_bib41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2004.09.006","article-title":"High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA\/PEGASE 04 protocol","volume":"41","author":"Lotz","year":"2005","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2006.07.086_bib42","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1200\/JCO.1999.17.5.1425","article-title":"Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer","volume":"17","author":"Valero","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2006.07.086_bib43","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2006.07.086_bib44","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.ejca.2005.12.011","article-title":"A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)","volume":"42","author":"Coleman","year":"2006","journal-title":"Eur J Cancer"},{"issue":"22","key":"10.1016\/j.biopha.2006.07.086_bib45","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1200\/JCO.2001.19.22.4216","article-title":"Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer","volume":"19","author":"Perez","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.biopha.2006.07.086_bib46","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1200\/JCO.2002.08.129","article-title":"Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer","volume":"20","author":"Loesch","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2006.07.086_bib47","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1200\/JCO.2000.18.6.1212","article-title":"Docetaxel administered on a weekly basis for metastatic breast cancer","volume":"18","author":"Burstein","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2006.07.086_bib48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ctrv.2005.12.008","article-title":"Vinorelbine in the management of breast cancer: new perspectives, revived role in the era of targeted therapy","volume":"32","author":"Mano","year":"2006","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"10.1016\/j.biopha.2006.07.086_bib49","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3816\/CBC.2006.n.005","article-title":"Capecitabine\/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer","volume":"6","author":"Nole","year":"2006","journal-title":"Clin. Breast Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2006.07.086_bib50","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1517\/14740338.4.5.915","article-title":"Oral versus intravenous vinorelbine: clinical safety profile","volume":"4","author":"Gebbia","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"issue":"7","key":"10.1016\/j.biopha.2006.07.086_bib51","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A","article-title":"Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients","volume":"92","author":"Blum","year":"2001","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2006.07.086_bib52","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s00280-005-0092-6","article-title":"Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial","volume":"57","author":"Bartsch","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2006.07.086_bib53","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.1995.13.2.513","article-title":"Use of tamoxifen for breast cancer: twenty-eight years later","volume":"13","author":"Jaiyesimi","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2006.07.086_bib54","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1634\/theoncologist.9-5-489","article-title":"Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability","volume":"9","author":"Mouridsen","year":"2004","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.biopha.2006.07.086_bib55","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1023\/B:BREA.0000025420.78346.f9","volume":"85","author":"Thurlimann","year":"2004","journal-title":"Breast Cancer Res. Treat."},{"issue":"11","key":"10.1016\/j.biopha.2006.07.086_bib56","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1200\/JCO.2000.18.11.2234","article-title":"Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial","volume":"18","author":"Lonning","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2006.07.086_bib57","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/jnci\/87.10.746","article-title":"Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer","volume":"87","author":"Osborne","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"issue":"9","key":"10.1016\/j.biopha.2006.07.086_bib58","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1200\/JCO.2004.02.112","article-title":"Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial","volume":"22","author":"Howell","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2006.07.086_bib59","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF01990032","article-title":"Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer","volume":"18","author":"Macheledt","year":"1991","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.biopha.2006.07.086_bib60","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF01806190","article-title":"Tamoxifen and interferon-beta for the treatment of metastatic breast cancer","volume":"39","author":"Repetto","year":"1996","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.biopha.2006.07.086_bib61","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0960-9776(97)90572-5","article-title":"Combination of interferon and tamoxifen for patients with advanced breast cancer and negative oestrogen receptors","volume":"6","author":"Peretz","year":"1997","journal-title":"Breast"},{"key":"10.1016\/j.biopha.2006.07.086_bib62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/jir.1998.18.41","article-title":"Minimal residual disease in metastatic breast cancer: treatment with IFN-beta, retinoids, and tamoxifen","volume":"18","author":"Recchia","year":"1998","journal-title":"J. Interferon Cytokine Res."},{"issue":"10","key":"10.1016\/j.biopha.2006.07.086_bib63","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/1097-0142(19871115)60:10<2419::AID-CNCR2820601011>3.0.CO;2-S","article-title":"Effect of natural beta-interferon on cell proliferation and steroid receptor level in human breast cancer cells","volume":"60","author":"Sica","year":"1987","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2006.07.086_bib64","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.biopha.2004.05.019","article-title":"Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial","volume":"59","author":"Nicolini","year":"2005","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.biopha.2006.07.086_bib65","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/01.cji.0000156827.67572.53","article-title":"An immunotherapy schedule in endocrine-dependent metastatic breast cancer: correlation between clinical course and immunologic parameters","volume":"28","author":"Nicolini","year":"2005","journal-title":"J. Immunother."},{"issue":"11","key":"10.1016\/j.biopha.2006.07.086_bib66","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.biopha.2006.07.086_bib67","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.2003.02.018","article-title":"Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm","volume":"21","author":"Burstein","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2006.07.086_bib68","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1634\/theoncologist.11-4-318","article-title":"Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy","volume":"11","author":"Montemurro","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2006.07.086_bib69","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.biopha.2003.09.009","article-title":"Anti-angiogenic therapy in breast cancer","volume":"57","author":"Rahman","year":"2003","journal-title":"Biomed. Pharmacother."},{"issue":"21 Suppl 5","key":"10.1016\/j.biopha.2006.07.086_bib70","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1093\/ajhp\/61.suppl_5.S21","article-title":"Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor","volume":"61","author":"Ignoffo","year":"2004","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2006.07.086_bib71","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF02968291","article-title":"Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer","volume":"11","author":"Saji","year":"2004","journal-title":"Breast Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2006.07.086_bib72","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1200\/JCO.2002.20.3.707","article-title":"Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer","volume":"20","author":"Nieto","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2006.07.086_bib73","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1524-4741.2002.08002.x","article-title":"Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease","volume":"8","author":"Rivera","year":"2002","journal-title":"Breast J."},{"issue":"8","key":"10.1016\/j.biopha.2006.07.086_bib74","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.1996.14.8.2197","article-title":"Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer","volume":"14","author":"Greenberg","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2006.07.086_bib75","first-page":"1039","article-title":"Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer","volume":"27","author":"Recchia","year":"2005","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2006.07.086_bib76","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/01.cji.0000186244.85058.1b","article-title":"Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer","volume":"29","author":"Recchia","year":"2006","journal-title":"J. Immunother."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332206002496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332206002496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:38:43Z","timestamp":1760092723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332206002496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0753332206002496"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2006.07.086","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metastatic breast cancer: an\u00a0updating","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2006.07.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}